Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0242706 (
hyperoxia
)
5,219
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Hyperoxia
and tumor necrosis factor-alpha (TNFalpha) are two canonical signals centrally involved in the pathophysiology of acute lung injury. We have attempted to elucidate the effects of these two stimuli on the signal transduction pathways of lung parenchymal cells. In cultured human lung epithelial cells, exposure to
hyperoxia
alone (95% oxygen) did not affect NF-kappaB activation or degradation of the NF-kappaB inhibitory protein,
IkappaB alpha
. Stimulation with TNFalpha alone increased NF-kappaB activation within 1 h and induced
IkappaB alpha
degradation within 0.5 h. After TNFalpha alone, NF-kappaB activation returned to baseline within 2 h and this corresponded with near complete
IkappaB alpha
resynthesis within 1 h of stimulation. In contrast, simultaneous exposure to
hyperoxia
and TNFalpha prolonged NF-kappaB activation up to 4 h, and
IkappaB alpha
degradation up to 2 h after stimulation.
Hyperoxia
did not affect TNFalpha-mediated resynthesis of
IkappaB alpha
mRNA.
Hyperoxia
alone did not induce IkappaB kinase (IKK) activity, but significantly prolonged TNFalpha-mediated activation of IKK activity.
Hyperoxia
alone did not activate the intercellular adhesion molecule-1 (ICAM-1) promoter, but augmented TNFalpha-mediated activation of the ICAM-1 promoter. These data demonstrate that while
hyperoxia
alone does not affect activation of NF-kappaB,
hyperoxia
prolongs TNFalpha-mediated activation of NF-kappaB. The mechanism of this effect involves, in part, prolonged degradation of
IkappaB alpha
resulting from prolonged activation of IKK.
...
PMID:Hyperoxia prolongs tumor necrosis factor-alpha-mediated activation of NF-kappaB: role of IkappaB kinase. 1195 26